Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2015.147 | A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2 |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2014.635 | Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world | Dr. WONG Raymond Siu Ming |
| 2015.010 | The hepato-protective effects of umbilical cord-derived stem cell on acetaminophen induced liver injury. | Dr. WONG Raymond Siu Ming |
| 2014.269 | A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-risk myelodysplastic syndrome (MDS) | Dr. WONG Raymond Siu Ming |
| 2017.452 | A Phase Ib, Open Label, Multiple Ascending Dose, Pilot Study to Assess the Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH). – PADDOCK – |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2017.267 | A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-4 |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2024.390 | The disease epidemiology and treatment of haemophilia A and B patients in Hong Kong |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2012.257 | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma | Dr. WONG Raymond Siu Ming |
| 2014.111 | A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. | Dr. WONG Raymond Siu Ming |
| 2012.292 | A Phase 1 Pharmacokinetic and Tolerability Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma | Dr. WONG Raymond Siu Ming |
| 2011.278 | A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy | Dr. WONG Raymond Siu Ming |
| 2012.305 | A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment. | Dr. WONG Raymond Siu Ming |
| 2013.269 | A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DIFFUSE LARGE B-CELL LYMPHOMA OR CD20+ FOLLICULAR NON-HODGKIN’S LYMPHOMA GRADES 1, 2 OR 3A | Dr. WONG Raymond Siu Ming |
| 2006.286 | EXTEND (Eltrombopag eXTENded Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, with Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in An Eltrombopag Study | Prof. WONG Raymond Siu Ming |
| 2009.457 | An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 +chlorambucil (GClb), rituximab + chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities | Dr. WONG Raymond Siu Ming |
| 2013.430 | AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 | Dr. WONG Raymond Siu Ming |
| 2014.112 | Study 200170: A Rollover Study to Provide Continued Treatment with Eltrombopag. | Dr. WONG Raymond Siu Ming |
| 2011.395 | A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension). | Dr. WONG Raymond Siu Ming |
| 2009.489 | A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and tranfusional iron overload (TELESTO) | Dr. WONG Raymond Siu Ming |
| 2008.068 | A Phase 1 / 2 Study of CMC-544 Administered in Combination with Rituximab in Subjects with Follicular or Diffuse Large B-Cell Non-Hodgkin’s Lymphoma | Prof. WONG Raymond Siu Ming |
| 2011.479 | An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B | Dr. WONG Raymond Siu Ming |
| 2010.030 | A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma | Dr. WONG Raymond Siu Ming |
| 2011.538 | An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A | Dr. WONG Raymond Siu Ming |
| 2009.494 | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman Disease | Dr. WONG Raymond Siu Ming |
| 2012.419 | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Dr. WONG Raymond Siu Ming |
| 2009.308 | A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With Indolent Non-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or Radioimmunotherapy | Dr. WONG Raymond Siu Ming |
| 2009.309 | An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed / Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Transplantation | Dr. WONG Raymond Siu Ming |
| 2014.006 | Myeloproliferative neoplasms Epidemiological Registry in Growing and Emerging markets - The MERGE Study | Dr. WONG Raymond Siu Ming |
| 2012.400 | Paroxysmal Nocturnal Hemoglobinuria (PNH) registry | Dr. WONG Raymond Siu Ming |
| 2020.692 | A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOMITANT JAK2 INHIBITOR THERAPY AND WHO REQUIRE RED BLOOD CELL TRANSFUSIONS The “INDEPENDENCE” Trial |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.229 | Real-world Evidence of the Use of Carfilzomib Among Patients With Relapsed/Refractory Multiple Myeloma in Asia Pacific |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2020.156 | A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2020.576 | A Study to Describe the Real-world Use of Dasatinib Treatment for Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukaemia (CML) | Dr. WONG Raymond Siu Ming |
| 2019.512 | A retrospective analysis of risk factors and outcomes of cancer-associated venous thromboembolism in Chinese patients | Dr. WONG Raymond Siu Ming |
| 2019.481 | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF REGN3918 IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Dr. WONG Raymond Siu Ming |
| 2019.286 | A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2018.471 | An Open-label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of PEGCETACOPLAN in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2024.394 | Mycophenolate mofetil in Chinese patients with immune thrombocytopenia | Dr. WONG Raymond |
| 2008.042 | A Phase 3 Randomized, Open-label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Phildadelphia Chromosome Positive Chronic Myelogenous Leukemia | Dr. WONG Raymond |
| 2022.134 | Impact of cholesterol level on long-term angiographic outcome of CABG patients | Dr. WONG Randolph Hung Leung |
| 2024.067 | AI-powered Multimodality approach to screen and diagnose Thoracic Aortic Aneurysm and Dissection (TAAD) |
Prof. WONG Randolph Hung Leung 黃鴻亮 |
| 2023.286 | Frailty trajectories and factors associated with frailty change among patients undergoing cardiac surgeries or transcatheter procedures: a mixed-methods prospective longitudinal study | Prof. WONG Randolph Hung Leung |
| 2021.236 | NEOS-APAC – Asian Pacific post-market clinical follow-up study in patients with acute or chronic aortic dissection or aortic aneurysm treated with E-vita OPEN NEO |
Dr. WONG Randolph Hung Leung 黃 鴻 亮 |
| 2022.083 | Radiogenomics approach to determine the prevalence of Genetically Triggered Thoracic Aortic Aneurysm and Dissection and guide genetic counselling in Hong Kong |
Dr. WONG Randolph Hung Leung 黃鴻亮 |
| 2024.110 | Determinants of early and late survival after surgery for cardiac tumours |
Prof. WONG Randolph Hung Leung 黃鴻亮 |
| 2024.109 | Determinants of event-free survival and late reintervention after the Bentall procedure: A single-centre retrospective study |
Prof. WONG Randolph Hung Leung 黃鴻亮 |
| 2023.075 | Randomized trial on Acutely Dissected Aorta Repair with Hemiarch replacement with or without stent implantation (RADAR trial) |
Prof WONG Randolph Hung Leung 黃鴻亮 |
| 2015.669 | Pocket-size mobile echocardiographic device screening for thoracic aortic aneurysm in Chinese hypertensive patients |
Dr. WONG Randolph Hung Leung 黃鴻亮 |
| 2018.262 | Quantitative assessment of the spondyloarthritis severity by using Diffusion Weighted Imaging in 3T magnetic resonance imaging. |
Dr. WONG Priscilla Ching Han 王靜嫻 |
| 2020.081 | Characterising Right Ventricular Fibrosis and Abnormal Strain in Systemic Lupus Erythematosus with Pulmonary Hypertension – a Magnetic Resonance Imaging and Echocardiographic Correlation Study |
Dr. WONG Priscilla Ching Han 王靜嫻 |
Page 28 of 254.